Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.55 USD | -3.79% | -14.87% | -85.71% |
May. 14 | Wolfe Research Downgrades RAPT Therapeutics to Peer Perform From Outperform | MT |
May. 10 | Guggenheim Downgrades RAPT Therapeutics to Neutral From Buy | MT |
Business Summary
Number of employees: 126
Managers
Managers | Title | Age | Since |
---|---|---|---|
Brian Wong
CEO | Chief Executive Officer | 52 | 15-07-31 |
Rodney Young
DFI | Director of Finance/CFO | 61 | 19-12-01 |
Jim Farmer
CTO | Chief Tech/Sci/R&D Officer | - | 22-05-03 |
William Ho
CTO | Chief Tech/Sci/R&D Officer | 58 | 15-04-30 |
Dirk Brockstedt
CTO | Chief Tech/Sci/R&D Officer | 55 | 17-12-31 |
Nipun Davar
CTO | Chief Tech/Sci/R&D Officer | - | Feb. 12 |
Investor Relations Contact | 63 | - | |
General Counsel | - | 23-05-02 | |
Adnan Rahman
PRN | Corporate Officer/Principal | - | 22-09-27 |
Shari L. Geffon
PRN | Corporate Officer/Principal | - | 22-05-03 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Mary Gray
BRD | Director/Board Member | 71 | 19-12-03 |
William Rieflin
CHM | Chairman | 64 | 15-04-30 |
Wendye Robbins
BRD | Director/Board Member | 63 | 19-10-21 |
Brian Wong
CEO | Chief Executive Officer | 52 | 15-07-31 |
Michael Giordano
BRD | Director/Board Member | 66 | 17-12-31 |
Linda Kozick
BRD | Director/Board Member | 66 | 16-11-30 |
Director/Board Member | 46 | 21-11-08 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 34,799,702 | 32,933,918 ( 94.64 %) | 0 | 94.64 % |
Company contact information
Sector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-85.39% | 129M | |
+16.79% | 124B | |
+16.80% | 109B | |
-7.27% | 23.84B | |
+1.98% | 22.42B | |
-14.29% | 17.5B | |
-6.34% | 16.61B | |
-37.63% | 16.43B | |
+2.16% | 13.4B | |
+24.36% | 11.47B |
- Stock Market
- Equities
- RAPT Stock
- Company RAPT Therapeutics, Inc.